Neurobiology and molecular biology of Alzheimer's disease;Neurobiología y biología molecular de la enfermedad de Alzheimer

Revista de Neurologia

Volumn 35, Issue 8, 2002, Pages 752-760

  DeKosky, Steven T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Alzheimer's disease; Neuritic plaques; Neurofibrillary tangles; Neuropathology

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ANIMAL MODEL; APOPTOSIS; CHOLINERGIC SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE MUTATION; LIMBIC SYSTEM; MOLECULAR BIOLOGY; MOUSE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; POSTSYNAPTIC INHIBITION; PROTEIN INTERACTION; PROTEIN METABOLISM; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; LOCUS COERULEUS; MICE; MICE, TRANSGENIC; MODELS, NEUROLOGICAL; NEUROFIBRILLARY TANGLES; NEUROTRANSMITTER AGENTS; RECEPTORS, NEUROTRANSMITTER; SENILE PLAQUES; SYNAPSES;

EID: 0037121147     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (126)

1. Imahori K, Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem 1997; 121: 179-88.
2. Terry RD, Peck A, De Teresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 1010: 184-92.
3. Mann DM, Marcyniuk B, Yates PO, Neary D, Snowden JS. The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy. Neuropathol Appl Neurobiol 1988; 14: 177-95.
4. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989; 135: 309-19.
5. Mann DM, Esiri MM. The site of the earliest lesions of Alzheimer's disease [letter]. N Engl J Med 1988; 318: 789-90.
6. Braak H, Braak E. Neuropathological staging of Alzheimer's disease. Acta Neuropathol 1991; 82: 239-59.
7. Mann DMA, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 1989; 89: 169-79.
8. Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990; 11: 29-37.
9. Scheff SW, Price DA. Synapse Loss in the Temporal Lobe in Alzheimer's Disease. Ann Neurol 1993; 33: 190-9.
10. Zhan S, Beyreuther K, Schmitt H. Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Dementia 1993; 4: 66-74.
11. Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer's disease and other dementias. Neurology 1989; 39: 355-61.
12. Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA. Cortical and subcortical patterns of synaptophysin-like immunoreactivity in Alzheimer's disease. Am J Pathol 1991; 138: 235-46.
13. Honer WG, Dickson DW, Gleeson J, Davies P. Regional synaptic pathology in Alzheimer's disease. Neurobiol Aging 1992; 13: 375-82.
14. Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987; 78: 151-64.
15. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457-64.
16. Terry RD, Masliah E, Salmon DP, Butters N, De Teresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-80.
17. Ohtsubo K, Izumiyama N, Shimada H, Tachikawa T, Nakamua H. Three-dimensional structure of Alzheimer's neurofibrillary tangles of the aged human brain revealed by the quick-freeze, deep-etch and replica method. Acta Neuropathol 1990; 79: 480-5.
18. Terry RD, Masliah E, Hansen LA. Structural basis of the cognitive alterations in Alzheimer disease. In Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press; 1994. p. 179-96.
19. Blessed G, Tomlinson B, Roth M. The association between quantitative measures of dementia and of senile changes in cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811.
20. Hof P, Morrison JH. The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. In Terrry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press; 1994. p. 197-229.
21. Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41: 17-24.
22. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: The Nun Study. JAMA 1997; 277: 813-7.
23. Brun A, Englund B, Gustafson L, Passant U, Mann DMA, Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia: The Lund and Manchester groups. J Neurol Neurosurg Psychiatry 1994; 57: 416-8.
24. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol 1997; 41: 706-15.
25. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998; 43: 815-25.
26. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-5.
27. Hong M, Khukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998; 282: 1914-7.
28. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci 1998; 95: 7737-41.
29. Conrad C, Andreadis CC, Trojanowski JQ, Dickson DW, Kang D, Chen X, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997; 41: 277-81.
30. Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and parkinsonism linked to Chromosome 17: a new group of tauopathies. Brain Pathol 1998; 8: 387-402.
31. Feany MB, Dickson DW. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 1996; 40: 139-48.
32. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys Res Commun 1984; 120: 885-90.
33. Selkoe DJ. Alzheimer's disease: genotypes, phenotype, and treatments. Science 1997; 275: 630-1.
34. Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994; 53: 438-47.
35. Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, et al. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain [published erratum appears in J Neurochem 1997; 68: 1331]. J Neurochem 1996; 67: 1882-96.
36. Haass C, Selkoe DJ. Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide. Cell 1993; 75: 1039-42.
37. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer's disease b-secretase activity. Nature 1999; 402: 533-7.
38. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 1999; 402: 537-40.
39. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-41.
40. Mann DMA, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, et al. Amyloid beta protein deposition in chromosome 14-linked Alzheimer's disease: predominance of Aβ 42(43). Ann Neurol 1996; 40: 149-56.
41. Li YT, Woodruffpak DS, Trojanowski JQ. Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites. Neurobiol Aging 1994; 15: 1-9.
42. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994; 13: 45-53.
43. Tamaoka A, Sawamura N, Odaka A, Suzuki N, Mizusawa H, Shoji S, et al. Amyloid beta protein 1-42/43 (Aβ 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res 1995; 679: 151-6.
44. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. Evidence that the 42- and 40-amino acid forms of amyloid protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci 1996; 93: 13170-5.
45. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-91.
46. McGeer EG, McGeer PL, Kamo H, Tago H, Harrop R. Cortical metabolism, acetylcholinesterase staining and pathological changes in Alzheimer's disease. Can J Neurol Sci 1986; 13: 511-16.
47. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988; 9: 339-49.
48. Griffin WST, Stanley LC, Ling C, White L, Macleod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down Syndrome and Alzheimer's disease. Proc Natl Acad Sci U S A 1989; 86: 7611-5.
49. Styren SD, Civin HW, Rogers J. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's diseased brain. Exp Neurol 1990; 110: 93-104.
50. Perlmutter LS, Scott SA, Barron E, Chui HC. MHC Class II-Positive microglia in human brain: association with Alzheimer lesions. J Neurosci Res 1992; 33: 549-58.
51. Mrak RE, Sheng JG, Griffin WST. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol 1995; 26: 816-23.
52. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer's and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195.
53. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, et al. Microglial activation resulting from CD40-CD40L interaction after b-amyloid stimulation. Science 1999; 286: 2352-5.
54. Mattson MP. Advances fuel Alzheimer's conundrum. Nat Genet 1997; 17: 254-6.
55. Goate A, Chartier-Harlin M, Mullan M, Brow NJ, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6.
56. St George-Hyslop PH. The molecular genetics of Alzheimer disease. In Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press; 1994. p. 345-67.
57. Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258: 668-71.
58. van Broeckhoven C, Backhovens H, Cruts M, de Winter G, Bruyland M, Cras P. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat Genet 1992; 2: 335-9.
59. Mullan MH, Windelspecht M. A locus for familial early onset Alzheimer's disease on the long arm of chromosome 14 proximal to the alpha-1-antichymotrypsin gene. Nat Genet 1992; 2: 340-3.
60. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus [see comments]. Science 1995; 269: 973-7.
61. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, et al. A familial Alzheimer's disease locus on chromosome 1 [see comments]. Science 1995; 269: 970-3.
62. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376: 775-8.
63. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20: 154-9.
64. Guo Q, Sopher BL, Furukawa K, Pham DG, Robinson N, Martin GM, et al. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J Neurosci 1997; 17: 4212-22.
65. Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacana E, Sunderland T, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 1996; 274: 1710-3.
66. Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, et al. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci U S A 1996; 93: 14940-4.
67. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3.
68. Roses AD. Apolipoprotein E in neurology. Curr Opin Neurol 1996; 9: 265-70.
69. Myers RH, Schaefer EJ, Wilson PWF, D'Agostino R, Ordovas JM, Espino A, et al. Apolipoprotein E ε4 associated with dementia in a population-based study: The Framingham Study. Neurology 1996; 44: 673-7.
70. Hyman BT, Gómez-Isla T, Briggs M, Chung H, Nichols S, Kohout F, et al. Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 1996; 40: 55-66.
71. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Locascio JJ, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996; 39: 62-70.
72. Namba Y, Tomoanga M, Kawasaki H, Otomo E, Ikeda K. Apolipo-protein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991; 541: 163-6.
73. Wisniewski T, Castano EM, Golabek A, Volgel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994; 145: 1030-5.
74. Sheng JS, Mrak RE, Griffin WST. Apolipoprotein E distribution among different plaque types in Alzheimer's disease: Implications for its role in plaque progression. Neuropathol Appl Neurobiol 1996; 22: 334-41.
75. Ma J, Yee A, Brewer HBJ, Das S. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994; 372: 92-4.
76. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 alelle in late-onset familial Alzheimer disease. Proc Natl Acad Sci 1993; 90: 1977-81.
77. Strittmatter WJ, Weisgraber KH, Goedert M, Saunders AM, Huang D, Corder EH, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol 1994; 125: 163-71.
78. Johnson EM Jr. Possible role of neuronal apoptosis in Alzheimer's disease. Neurobiol Aging 1994; 15 (Suppl 2): S187-9.
79. Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol 1996; 6: 493-506.
80. Cotman CW, Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 1995; 10: 19-45.
81. Tatton WG, Chalmers-Redman RM, Ju WY, Wadia J, Tatton NA. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm Suppl 1997; 49: 245-68.
82. Hajimohamadreza I, Treheme JM. The role of apoptosis in neurodegenerative diseases. Prog Drug Res 1997; 48: 55-98.
83. Kusiak JW, Izzo JA, Zhao B. Neurodegeneration in Alzheimer disease. Is apoptosis involved? Mol Chem Neuropathol 1996; 28: 153-62.
84. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein [see comments]. Nature 1995; 373: 523-7.
85. Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995; 15: 1203-18.
86. Price DL, Becher MW, Wong PC, Borchelt DR, Lee MK, Sisodia SS. Inherited neurodegenerative diseases and transgenic models. Brain Pathol 1996; 6: 467-80.
87. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997; 17: 7053-9.
88. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 1997; 17: 263-4.
89. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-91.
90. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
91. Neary D, Snowden JS, Mann DM, Bowen DM, Sims NR, Norther B, et al. Alzheimer's disease: a correlative study. J Neurol Neurosurg Psychiatry 1986; 49: 229-37.
92. DeKosky ST, Harbaugh RE, Schmitt FA, Bakay RE, Knopman DS, et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological and cognitive correlations. Ann Neurol 1992; 32: 625-32.
93. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-17.
94. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm 1993; 91: 135-59.
95. Zubenko GS, Moossy J, Martínez AJ, Rao G, Classen D, Rosen J, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991; 48: 619-24.
96. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of depression in primary dementia. Arch Neurol 1990; 47: 209-14.
97. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
98. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99: 459-96.
99. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; 1: 189.
100. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978; 2: 1457-9.
101. Davies P, Verth AH. Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's type dementia brains. Brain Res 1977; 138: 385-92.
102. Sims NR, Bowen DM, Allen SJ, Smith CCT, Neary D, D.J. T, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983; 40: 503-9.
103. Flynn DD, Weinstein DA, Mash DC. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol 1991; 29: 256-62.
104. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA 1999; 281: 1401-6.
105. DeKosky ST, Ikonomovic MD, Styren SD, Paulin M, Wisniewski S, Cochran E, et al. Cortical and hippocampal ChAT activity in normal aging, mild cognitive impairment, and mild Alzheimer's disease. Soc Neurosci 1999; 25: 2117.
106. Mash DC, Flynn DD, Potter LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Sience 1985; 228: 1115-7.
107. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996; 40: 399-410.
108. Kish SJ, Distefano LM, Dozic S, Robitaille Y, Rajput A, Deck JH, et al. [3H]vesamicol binding in human brain cholinergic deficiency disorders. Neurosci Lett 1990; 117: 347-52.
109. Ruberg M, Mayo W, Brice A, Duyckaerts C, Hauw JJ, Simon H, et al. Choline acetyltransferase activity and [3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions. Neuroscience 1990; 35: 327-33.
110. Araujo DM, Lapchak PA, Robitaille Y, Quirion R. Differential alteration of various cholinergic markers in cortical and subcorfical regions of human brain in Alzheimer's disease. J Neurochem 1988; 50: 1914-23.
111. Pearce BD, Potter LT. Coupling of M1 muscarinic receptors to G protein in Alzheimer's disease. Alz Dis Assoc Disord 1991; 5: 163-72.
112. Francis PT, Cross AJ, Bowen DM. Neurotranmitters and neuropeptides. In Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven Press; 1994. p. 247-61.
113. Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988; 24: 233-42.
114. Yamamoto S, Hirano A. Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann Neurol 1985; 17: 573-7.
115. Rossor M, Emson P, Dawbarn D, Dockray G, Mountjoy C, Roth M. Postmortem studies of peptides in Alzheimer's disease and Huntington's disease. Assoc Res Nerv Mental Dis 1986; 64: 259-77.
116. Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982; 32: 164-8.
117. Marcyniuk B, Mann DMA, Yates PO. The topography of cell loss from locus coeruleus in Alzheimer's disease. J Neurol Sci 1986; 76: 335-45.
118. Mann DMA, Lincoln J, Yates PO, Stamp JE, Toper S. Changes in the monoamine containing neurons of the human CNS in senile dementia. Br J Psychiatry 1980; 136: 533-41.
119. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
120. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathological entity. Neurology 1990; 40: 1-8.
121. Young AD. Causes of Alzheimer's disease. In Khatchaturian Z, Radebaugh T, eds. Alzheimer's disease: cause(s), diagnosis, treatment, and care. New York: CRC Press; 1996. p. 227-32.
122. Procter AW, Lowe SL, Palmer AM, Francis PT, Esiri MM, Stratmann GC, et al. Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci 1988; 84: 125-40.
123. Proctor AW, Palmer AM, Francis PT, Lowe SL, Neary D, Murphy E, et al. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem 1988; 50: 790-802.
124. Palmer AM. Excitatory amino acid neurons and receptors in Alzheimer's Disease. In Kozikowski AP, Barrionuevo G, eds. Neurobiology of the NMDA receptor: from chemistry to clinic. New York: VCH Publishers; 1991. p. 203-37.
125. Nemeroff CB, Bissette G, Slotkin TA, Seidler FJ, Miller BE, Ghanbari H. Recent advances in the neurochemical pathology of Alzheimer's disease. Studies of neuropeptides, cholinergic function and Alzheimer's disease-associated protein. Ann N Y Acad Sci 1991; 640: 193-6.
126. Hartline KM, Owens MJ, Nemeroff CB. Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Ann N Y Acad Sci 1996; 780: 96-105.